Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00111306
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
510
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
epratuzumab
Sponsor
UCB Pharma